LV009
/ PersonGen Biomedicine
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
January 10, 2026
Clinical Study of LV009 Injection in the Treatment of Recurrent/Refractory CD19 Positive Blood Tumors
(clinicaltrials.gov)
- P1 | N=19 | Not yet recruiting | Sponsor: The First Affiliated Hospital with Nanjing Medical University
New P1 trial • Hematological Malignancies • Lymphoma • Oncology
January 01, 2026
Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies
(clinicaltrials.gov)
- P1 | N=19 | Recruiting | Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.
New P1 trial • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
December 17, 2025
Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies
(clinicaltrials.gov)
- P1 | N=10 | Recruiting | Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.
New P1 trial • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
October 31, 2025
Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies
(ChiCTR)
- P=N/A | N=19 | Not yet recruiting | Sponsor: The First Affiliated Hospital of the University of Science and Technology of China; The First Affiliated Hospital of the University of Science and Tec
New trial • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
1 to 4
Of
4
Go to page
1